Table 1.
Patient characteristics of 401 advanced stage cHL patients treated within clinical trials HD12 and HD15 and prediction analysis of the adjusted gene predictor.
| A. Patient characteristics with risk groups resulting from the adjusted gene predictor | ||||||
|---|---|---|---|---|---|---|
| All | High risk | Low risk | ||||
| N = 401 | N = 149 | N = 252 | ||||
| N | % | N | % | N | % | |
| Age (years) | ||||||
| Median | 33 | 39 | 29 | |||
| Range | 18–60 | 18–60 | 18–59 | |||
| 18–45 | 317 | 79.1 | 103 | 69.1 | 214 | 84.9 |
| 45–60 | 84 | 20.9 | 46 | 30.9 | 38 | 15.1 |
| Sex | ||||||
| Female | 153 | 38.2 | 38 | 25.5 | 115 | 45.6 |
| Male | 248 | 61.8 | 111 | 74.5 | 137 | 54.4 |
| cHL Subtype | ||||||
| Mixed cellularity | 116 | 28.9 | 65 | 43.6 | 51 | 20.2 |
| Nodular sclerosis | 257 | 64.1 | 74 | 49.7 | 183 | 72.6 |
| Lymphocyte-rich | 11 | 2.7 | 3 | 2 | 8 | 3.2 |
| Lymphocyte-depleted | 4 | 1 | 3 | 2 | 1 | 0.4 |
| cHL NOS | 13 | 3.2 | 4 | 2.7 | 9 | 3.6 |
| IPS (grouped) | ||||||
| 0–1 | 114 | 28.4 | 29 | 19.5 | 85 | 33.7 |
| 2–3 | 224 | 55.9 | 92 | 61.7 | 132 | 52.4 |
| 4–7 | 63 | 15.7 | 28 | 18.8 | 35 | 13.9 |
| Relapse/Death | ||||||
| None | 232 | 57.9 | 81 | 54.4 | 151 | 59.9 |
| Progression/Relapse only | 79 | 19.7 | 30 | 20.1 | 49 | 19.4 |
| Death only | 54 | 13.5 | 29 | 19.5 | 25 | 9.9 |
| Both | 36 | 9 | 9 | 6 | 27 | 10.7 |
| B. Overall survival (OS) | ||
|---|---|---|
| Variable | univar. P | multivar. P |
| Age | <0.0001 | <0.0001 |
| Sex (male) | 0.0513 | 0.1759 |
| adj. gene predictor | 0.0079 | 0.525 |
| C. Progression-free survival (PFS) | ||
|---|---|---|
| Variable | univar. P | multivar. P |
| Age | 0.0002 | 0.0006 |
| Sex (male) | 0.0014 | 0.0034 |
| adj. gene predictor | 0.1452 | 0.7881 |
| D. OS and PFS with IPS | ||
|---|---|---|
| Variable | OS | PFS |
| multivar. P | multivar. P | |
| IPS | 0.0036 | 0.0027 |
| adj. gene predictor | 0.1438 | 0.7199 |
| E. Adj. gene predictor and IPS risk factors | ||
|---|---|---|
| Variable | stand. estimate β | significance P |
| Intercept | −0.98 | <0.0001 |
| Sex (male) | 0.55 | <0.0001 |
| Age ≥ 45 yrs | 0.46 | <0.0001 |
| Leukocytes ≥ 15,000/ | 0.66 | <0.0001 |
| Hb < 10.5 g/dL | 0.52 | <0.0001 |
| Lymphocytes < 8% of WBC | 0.39 | 0.0223 |
| Albumin < 4 g/dL | −0.07 | 0.4928 |
| Stage IV | −0.11 | 0.2328 |
Multiple linear regression of adjusted gene predictor on IPS factors, R2 = 0.22.
(A) Characteristics of high-risk and low-risk patients analyzed in this study. (B) Cox regression of progression-free survival (PFS) on sex, age and the adjusted gene predictor. (C) Cox regression of overall survival (OS) on sex, age and the adjusted gene predictor. (D) Cox regressions of PFS and OS on the IPS and the adjusted gene predictor. (E) Multiple linear regression of the adjusted gene predictor on the seven risk factors of the IPS.